DelveInsight's 'Antibody-drug Conjugates Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline antibody-drug conjugates in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the antibody-drug conjugates competitive domain.

Key Takeaways from the Antibody-drug Conjugates Competitive Landscape Report

• Over 180+ antibody-drug conjugates companies are evaluating 300+ antibody-drug conjugates drugs in various stages of development, and their anticipated acceptance in the antibody-drug conjugates market would significantly increase market revenue. 
• Key antibody-drug conjugates companies such as NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others are evaluating new antibody-drug conjugates drugs to improve the treatment landscape.
• Promising antibody-drug conjugates pipeline drugs such as Zynlonta, Ladiratuzumab Vedotin, NBE-002, IMGN151, Camidanlumab tesirine, ADCT-602, ADCT-901, ADCT-701, ADCT-212, ADCT-601, IMGN-632, IMGC 936, IMGN-151, MYTX-011, M1231, STI-6129, Torpedo, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC, OBI 999, R 992, NAV-001, and others are under different phases of antibody-drug conjugates clinical trials.
• In April 2023, Mythic Therapeutics, announced preclinical data highlighting the potential of MYTX-011, its investigational cMET-targeting ADC, for treating a broader range of cMET+ cancers than other cMET-targeting ADCs in development. These data were presented as a poster at the American Association for Cancer Research Annual Meeting. MYTX-011 demonstrated higher internalization in cMET+ tumor cells and broader, more potent efficacy, including a greater than 3-fold increase in efficacy in mouse models of NSCLC, as compared to other cMET-targeting ADCs.
• In April 2023, Araris Biotech AG, announced the company delivered two poster presentations at this year's American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida. The presentations highlighted late-breaking preclinical data on anti-Nectin-4 and anti-HER2 ADCs generated using the company's proprietary linker technology. Both ADCs demonstrated improved anti-tumor activity compared to respective FDA-approved ADCs in head-to-head in-vivo studies.
• In March 2022, Sanofi and Seagen Inc. announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has one ADC in development.
• In December 2022, Merck and Kelun-Biotech, announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. Under the agreement, Kelun-Biotech has granted Merck exclusive global licenses to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies and exclusive options to obtain additional licenses for ADC candidates. Kelun-Biotech retains the right to research, develop, manufacture, and commercialize certain licensed and option ADCs for mainland China, Hong Kong, and Macau.
• In December 2022, Biosion USA, Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc., a leader in developing next-generation ADCs. In the joint research effort, Biosion leveraged its proprietary SynTracer® high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs.